Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page + ~! ~8 ]# ?( R0 Y
% H8 _9 `! t. e
& ~: W8 ]7 b! Z7 B0 L5 |& aSub-category:8 `* @, \2 ^% p4 w$ E1 o x" U. W
Molecular Targets ( U1 \: {$ L8 A I+ v
" u7 W& X' q) A2 h" P- [
7 L" u, @8 M3 b# i1 N
Category:+ {! q# R+ J- F
Tumor Biology % `4 N9 J* Y% h9 Z/ n @
3 Z4 c Y2 `% |+ v8 S3 c$ l2 B
9 |5 [+ v. f3 D4 z7 KMeeting:0 @2 v6 |9 k& s: G. E+ x
2011 ASCO Annual Meeting ( t4 [# s5 m) g. A* Y6 p/ m
( v4 C) e2 q6 [" m. [
5 P5 B) z9 `, A0 y/ G$ W" N6 m
Session Type and Session Title:
- l- N) F* ~. c2 j- d7 wPoster Discussion Session, Tumor Biology
* v8 Q9 S1 R- Z% M9 ^/ b, K- z9 ?' a. {, b, F
& Y* I1 K4 N! z8 r# kAbstract No:
. d2 U- V2 O V) V% D: w6 u10517 2 d# `. G7 |' \4 u4 e9 K' {5 o
( E; v0 a- u1 J/ _$ T2 k) |0 [" t! P$ K
" D( p6 \- r) O& l4 Y6 F" L) \) tCitation:5 l- E) c7 N/ F' v
J Clin Oncol 29: 2011 (suppl; abstr 10517)
1 B5 Q5 Q2 t4 p: {% {" W5 ` L4 v* H, r$ ~3 g
* @8 `5 l( m1 `* l1 k5 V* Y) x/ `Author(s):
$ N' X& `/ o# }- x! ]# Q+ xJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
7 \4 C) d0 L) ?* C1 u+ A/ `, j
( B5 H$ Y# ?7 f$ H9 Z, O, A4 y, F+ G( f8 M
0 L' j) d8 B9 ?+ dAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
8 w. g9 N |9 E9 }) C [2 w; ^9 w0 U! ]2 @6 L" I4 v1 p4 H }
Abstract Disclosures/ e2 r |1 R4 Z& o; H5 n
" o: ]0 e) X7 g1 K+ q
Abstract:# w N3 F1 r& ~ {+ S1 V8 W
& `8 K" T0 F# x
. @' X% g. ?7 q6 W5 k& i& R5 }/ T* [1 IBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.. I+ H+ H, h/ p( F
5 X) K- f' E& \! V
0 S: E1 b% z$ d* n1 W$ E
|